Encapsulating nucleic acids in lipid nanoparticles (LNPs) is the foundational step that determines whether a genetic medicine reaches its intracellular target or is cleared before producing any therapeutic effect. The process appears deceptively simple — mix lipids with nucleic acids under controlled conditions and nanoparticles self-assemble. Yet the gap between a formulation with 30% encapsulation efficiency (EE%) and one with >90% can represent months of optimization. This guide provides a practical, methodical approach to nucleic acid encapsulation in LNPs, covering method selection, payload-specific strategies, and systematic troubleshooting. Each section addresses the decisions formulation scientists face: which mixing technology to choose for a given nucleic acid cargo, how to adjust parameters when encapsulation fails, and when to seek external expertise.
The method chosen for LNP-nucleic acid assembly directly governs particle size distribution, encapsulation efficiency, payload integrity, and batch-to-batch reproducibility. These methods fall into three categories: self-assembly approaches that dominate modern LNP production, mechanical methods suited to specific scale or equipment constraints, and emerging techniques addressing niche encapsulation challenges.
Self-assembly methods exploit the thermodynamic drive of amphiphilic lipids to organize into ordered nanostructures when solvent conditions change abruptly — typically transitioning from a molecularly dispersed state in ethanol to an aqueous environment where hydrophobic lipid tails cluster inward and hydrophilic headgroups face outward. Nucleic acids present in the aqueous phase become entrapped during this rapid structural reorganization. Self-assembly approaches account for the vast majority of LNP production because they combine high encapsulation efficiency with excellent particle uniformity and straightforward scalability.
Microfluidic mixing has become the gold standard for nucleic acid-LNP assembly. A lipid-containing ethanol stream and a nucleic acid-containing aqueous buffer stream are brought into contact within a microfabricated channel, where controlled convective mixing drives nanoprecipitation and encapsulation in milliseconds. Channel geometry profoundly influences particle quality. T-junction designs bring streams together at a simple perpendicular intersection, suitable for preliminary screening but often producing broader size distributions. Herringbone and staggered herringbone micromixers (SHM) incorporate patterned grooves that induce chaotic advection — repeatedly stretching and folding fluid lamellae to achieve homogeneous mixing faster than nanoparticle nucleation and growth kinetics. The result is narrow polydispersity index (PDI) routinely below 0.1 and encapsulation efficiencies exceeding 90% for optimized formulations.
Flow rate ratio (FRR, typically 3:1 aqueous-to-organic) and total flow rate (TFR, 8–12 mL/min for bench-scale chips) are digitally controlled, making conditions precisely reproducible. The process is inherently scalable — the same mixing physics that produce 1 mg of LNP-formulated nucleic acid in a research chip can generate gram quantities when parallelized. For laboratories transitioning from discovery to preclinical development, microfluidic LNP production services provide access to this technology without requiring capital equipment investment.
Ethanol injection is the simplest self-assembly method: a lipid-ethanol solution is rapidly injected through a syringe needle into a stirred aqueous buffer containing the nucleic acid payload. The sudden drop in ethanol concentration triggers lipid precipitation and nanoparticle formation, entrapping nucleic acid molecules. The method requires only a syringe and stir plate, making it accessible to virtually any laboratory. However, mixing is macro-scale and diffusion-limited, producing a heterogeneous solvent environment and broader PDI (0.15–0.25). Encapsulation efficiencies can vary by 10–20% between replicates. Post-processing — extrusion through polycarbonate membranes or brief probe sonication — is often needed to narrow size distribution. Ethanol injection remains useful for early feasibility studies and lipid library screening where microfluidic chip cleaning throughput would be prohibitive.
Lipids are dissolved in organic solvent, deposited as a thin film by rotary evaporation, then hydrated with aqueous buffer containing the nucleic acid payload, producing multilamellar vesicles (MLVs) with encapsulated cargo. Repeated extrusion through polycarbonate membranes of defined pore size (100–200 nm) reduces diameter, narrows distribution, and converts MLVs into unilamellar structures. Encapsulation efficiencies are moderate (40–70%) because nucleic acid entrapment depends on passive inclusion during random vesicle closure rather than active electrostatic complexation. The method's principal advantage is compatibility with lipid compositions difficult to formulate by rapid mixing — such as formulations with very high cholesterol content.
Mechanical methods apply external physical forces — acoustic cavitation or high-pressure shear — to drive particle size reduction and encapsulation. These approaches start with pre-formed lipid structures and use energy input to reshape them, rather than relying on controlled solvent-mediated self-organization.
High-frequency sound waves (20–40 kHz) delivered through a probe immersed in the lipid-nucleic acid mixture generate microscopic cavitation bubbles that collapse violently, breaking down large lipid aggregates into nano-sized particles while promoting nucleic acid incorporation. Probe sonication is more effective than bath sonication because energy is focused at the probe tip. The critical limitation is payload damage: cavitation forces that reduce particle size can shear long RNA and DNA molecules, particularly mRNA and pDNA exceeding 1 kb. Gel electrophoresis of extracted nucleic acid post-sonication is essential to verify integrity. Power settings (20–40% amplitude), pulse mode (10 sec on/off), and total sonication time must be optimized for each nucleic acid species. Temperature control is equally important — samples should be maintained in an ice bath throughout processing.
High-pressure homogenization (HPH) forces a lipid-nucleic acid suspension through a narrow orifice at 500–2,000 bar, generating intense shear, turbulence, and cavitation that reduce particle size to the nanometer range. The process is continuous, with product recirculated through the homogenization valve for multiple passes. HPH offers clear scale-up advantages — commercial homogenizers can process liters to hundreds of liters per hour — but presents genuine challenges for nucleic acid encapsulation. Fluid temperatures can rise 10–20 °C per pass, creating conditions under which RNA degradation occurs. Encapsulation efficiencies are generally lower than microfluidic methods because the mixing mechanism does not create the same intimate contact between ionizable lipids and nucleic acids during nucleation. HPH is most appropriate when existing manufacturing infrastructure must be leveraged and when payloads are sufficiently robust — chemically modified oligonucleotides tolerate HPH conditions better than unmodified mRNA.
Detergent dialysis was historically the first method used to produce LNPs for nucleic acid delivery. Lipids and nucleic acids are co-solubilized with detergent (octyl glucoside or sodium cholate), which is gradually removed by dialysis against detergent-free buffer. As detergent concentration falls below its critical micelle concentration, lipids self-assemble into nanoparticles with entrapped nucleic acid. The slow, controlled process yields particles with well-defined internal structure but requires 24–48 hours. Modern adaptations replace dialysis with tangential flow filtration (TFF) for faster detergent removal, but encapsulation efficiencies remain lower than microfluidic methods. Dialysis-based methods are now used primarily for specialized lipid compositions that do not assemble properly under rapid mixing conditions.
Two high-velocity liquid jets — one carrying lipids in ethanol, the other carrying nucleic acid in aqueous buffer — are directed at each other in a confined mixing chamber. The collision generates intense turbulence and rapid mixing on a timescale comparable to microfluidics but without channel dimensions limiting flow rates. Impingement mixing platforms achieve production rates of liters per hour, making them attractive for clinical and commercial manufacturing. The trade-off is reduced control over mixing homogeneity compared to SHM-based microfluidics, manifesting as slightly broader PDI.
Electroporation takes a fundamentally different approach: rather than encapsulating nucleic acid during particle formation, it loads cargo into pre-formed empty LNPs. A brief, high-voltage electric pulse creates transient pores in the lipid membrane through which nucleic acid molecules diffuse into the particle interior. This post-loading strategy is conceptually attractive because it decouples particle formation from cargo loading. In practice, encapsulation efficiencies are low (20–40%) for large nucleic acids, and the electric field can induce degradation or aggregation. Electroporation is most applicable to small oligonucleotides (siRNA, miRNA, ASO) where passive diffusion through electroporation-induced pores is more efficient.
Table 1. Comparison of Nucleic Acid Encapsulation Methods for LNPs.
| Method | Category | Typical EE% | PDI Range | Scalability | Best Suited For |
| Microfluidic Mixing (SHM) | Self-Assembly | 85–95% | <0.10 | High — parallelizable | mRNA, siRNA, saRNA; preclinical to commercial |
| Ethanol Injection | Self-Assembly | 60–85% | 0.15–0.25 | Low — batch-to-batch variability | Early feasibility studies; lipid library screening |
| Film Hydration + Extrusion | Self-Assembly | 40–70% | 0.10–0.20 | Low — labor-intensive | Specialized lipid compositions; small-scale lab use |
| Ultrasonication | Mechanical | 50–75% | 0.15–0.25 | Low — probe-dependent | Small-batch preparation; short oligonucleotides |
| High-Pressure Homogenization | Mechanical | 40–65% | 0.15–0.30 | High — continuous processing | Chemically modified oligonucleotides; existing HPH infrastructure |
| Dialysis / Ultrafiltration | Emerging | 40–60% | 0.10–0.20 | Low — slow process | Specialized lipid compositions; research applications |
| Jet / Impingement Mixing | Emerging | 75–90% | 0.10–0.20 | High — L/hr production rates | Clinical and commercial manufacturing |
| Electroporation | Emerging | 20–40% | Variable | Low — batch process | Small oligonucleotide post-loading |
Tell us your nucleic acid type, target concentration, current formulation, and project difficulty. BOC Sciences can help define a practical encapsulation and evaluation plan.
Short oligonucleotides (15–30 nucleotides) present a paradoxical challenge: their small size makes them easy to load but difficult to retain. During microfluidic mixing, siRNA and ASO molecules readily complex with protonated ionizable lipids at acidic pH, routinely achieving encapsulation efficiencies above 90%. However, the same small size that facilitates loading also promotes leakage — short oligonucleotides diffuse out of LNPs more rapidly than larger nucleic acids during buffer exchange, storage, or serum exposure.
Effective retention begins with N/P ratio optimization. For siRNA and ASO, ratios of 3–6 provide the best balance of high encapsulation and sustained retention; ratios below 3 leave insufficient cationic lipid for charge neutralization, while ratios above 8 promote aggregation. Ionizable lipid pKa is particularly important: pKa of 6.0–6.5 ensures sufficient protonation at formulation pH (4.0–5.0) while remaining neutral at physiological pH. Cholesterol content above 30 mol% increases membrane rigidity and reduces leakage rates. For ASOs with extensive phosphorothioate modifications, additional PEG-lipid optimization (1.5–2.5 mol%) may prevent purification-induced aggregation. BOC Sciences provides lipid nanoparticles for siRNA delivery and lipid nanoparticles for ASO delivery with formulation parameters optimized for short oligonucleotide retention.
mRNA (1–5 kb) and self-amplifying RNA (saRNA, 9–12 kb) are the largest nucleic acid cargos routinely encapsulated in LNPs. Their length makes them susceptible to shear-induced fragmentation and RNase-mediated degradation throughout the formulation workflow. For mRNA, N/P ratios of 4–8 are typical — mRNA's greater phosphate content per molecule means more ionizable lipid is required for charge neutralization. Citrate buffer at pH 4.0–5.0 provides the acidic environment for ionizable lipid protonation while chelating divalent cations (Mg2+, Ca2+) that catalyze RNA hydrolysis. RNase-free water, nuclease-free consumables, and working temperatures of 4–10 °C are essential. Lipid nanoparticles for mRNA delivery developed by BOC Sciences incorporate these controls as standard, with encapsulation efficiencies routinely verified by fluorescence-based RNA quantification assay.
saRNA encapsulation introduces additional complexity. At 9–12 kb, saRNA contains extensive secondary structure (the alphavirus replicase complex) creating steric hindrance during electrostatic complexation with ionizable lipids. N/P ratios often require upward adjustment (6–10) to achieve acceptable encapsulation. Aggregation during formulation is common, driven by bridging of partially coated RNA molecules — increasing PEG-lipid to 2.0–3.0 mol% and reducing nucleic acid concentration in the aqueous phase mitigates this. Lower TFR (6–10 mL/min) during microfluidic mixing preserves saRNA integrity better than the higher rates used for mRNA. BOC Sciences offers lipid nanoparticles for saRNA delivery with parameters tailored to these extra-large cargo requirements.
Circular RNA (circRNA) is topologically distinct: the covalently closed loop eliminates free 5' and 3' ends, conferring exceptional exonuclease resistance but restricting conformational flexibility for electrostatic interaction with ionizable lipids. This can manifest as lower encapsulation efficiency when using formulation parameters optimized for linear mRNA. Strategies for improvement include increasing ionizable lipid mole fraction (from 40–50 mol% to 50–55 mol%) to provide additional positive charge density, and pre-compacting circRNA with low-concentration cationic polymer or peptide before microfluidic mixing to reduce its effective hydrodynamic radius. A slightly lower buffer pH (3.8–4.2) than typical for mRNA enhances ionizable lipid protonation and compensates for the reduced electrostatic accessibility of the circular structure. BOC Sciences provides lipid nanoparticles for circRNA delivery with formulation conditions specifically screened for circular RNA topology.
Plasmid DNA (pDNA, 3–10 kbp) and donor DNA templates for gene editing present the most challenging encapsulation scenario among nucleic acid cargos. pDNA's large hydrodynamic diameter — a 5-kbp plasmid behaves as a particle of approximately 50–100 nm in solution even before LNP encapsulation — means that pDNA-LNPs are inherently larger (80–150 nm) than their RNA-LNP counterparts. Mechanical forces during microfluidic mixing can convert supercoiled plasmid into relaxed or linear forms, reducing transfection efficiency. Lower TFR (4–8 mL/min), gentler mixing geometries (T-junction rather than SHM), and pre-condensation of pDNA with protamine or cationic peptides help preserve supercoiled topology. Helper lipid selection matters as well: DOPE, which favors the hexagonal (HII) phase that promotes endosomal membrane fusion, often outperforms DSPC for pDNA delivery. BOC Sciences provides lipid nanoparticles for pDNA delivery with formulation parameters specifically optimized for large DNA cargo integrity and transfection competence.
Co-encapsulation — loading two or more distinct nucleic acid species into the same LNP population — is increasingly relevant for combination therapies, gene editing applications, and vaccine designs that pair antigen-encoding mRNA with immunostimulatory oligonucleotides. The fundamental challenge is that different nucleic acid species compete for the same ionizable lipid binding sites during particle assembly, and their differing sizes and charge densities create thermodynamic preferences that can lead to heterogeneous loading: some particles predominantly carry one cargo while others carry the other.
Achieving homogeneous co-encapsulation requires careful balancing of input ratios. Pre-mixing the nucleic acids in the aqueous phase at the desired molar ratio before microfluidic mixing is essential — sequential addition produces heterogeneous populations. The N/P ratio must be calculated based on the total phosphate content of all nucleic acid species combined, not on the primary cargo alone. Post-formulation analysis should include methods capable of distinguishing the two cargos, such as dual-label fluorescence (e.g., Cy3/Cy5-labeled nucleic acids) with spectrophotometric quantification of each species in purified LNPs. Lipid nanoparticles for co-delivery from BOC Sciences are developed with systematic ratio screening to achieve uniform dual-cargo loading verified by independent quantification of each payload species.
Table 2. Payload-Specific Encapsulation Parameters for Major Nucleic Acid Types.
| Nucleic Acid Type | Typical Size | Key Challenge | Optimal N/P Ratio | Critical Formulation Parameter | Recommended Method |
| siRNA / miRNA | 15–30 nt | Payload leakage | 3–6 | Cholesterol >30 mol%; pKa 6.0–6.5 | Microfluidic mixing (SHM) |
| ASO | 15–25 nt | PS-modified aggregation | 3–6 | PEG-lipid 1.5–2.5 mol% | Microfluidic mixing (SHM) |
| mRNA | 1–5 kb | RNase degradation; shear | 4–8 | Buffer pH 4.0–5.0; temp 4–10 °C | Microfluidic mixing (SHM) |
| saRNA | 9–12 kb | Aggregation; shear of large RNA | 6–10 | PEG-lipid 2.0–3.0 mol%; TFR 6–10 mL/min | Microfluidic mixing (SHM, reduced TFR) |
| circRNA | 0.5–10 kb (circular) | Constrained electrostatic access | 5–9 | Ionizable lipid 50–55 mol%; pH 3.8–4.2 | Microfluidic mixing (SHM) |
| pDNA | 3–10 kbp | Shear sensitivity; large size | 6–12 | T-junction; DOPE helper lipid; TFR 4–8 mL/min | Gentle microfluidic (T-junction) or HPH |
BOC Sciences provides payload-specific support from experimental design and formulation development to performance verification, with solutions tailored to your requirements and designed to progress from laboratory studies to scalable production.
Even with careful method selection and payload-appropriate formulation parameters, encapsulation problems arise during development. The following troubleshooting guide addresses the six most frequently encountered challenges, organized by symptom with diagnostic indicators and actionable solutions. Each section assumes a methodical approach: verify the observation with quantitative data, identify the root cause from the differential diagnosis, and apply the solution most directly addressing that cause.
Symptom: EE% measured by RiboGreen or comparable fluorometric assay falls below 60%, or varies by >15% between replicate preparations using the same protocol.
Differential Diagnosis: The most common root cause is insufficient electrostatic interaction between the ionizable lipid and the nucleic acid. This can arise from (a) N/P ratio set too low for the specific nucleic acid length and charge density, (b) buffer pH during mixing being insufficiently acidic (above pH 5.0) to protonate the ionizable lipid, (c) ethanol fraction in the mixed stream being too low, causing lipid precipitation before adequate nucleic acid contact, or (d) TFR being too low to achieve the rapid mixing needed for homogeneous complexation.
Systematic Approach: First, verify buffer pH at 4.0 ± 0.2 with a calibrated pH meter; buffer pH drift during storage is a common but overlooked source of EE% variability. Second, screen N/P ratios from 2 to 10 in integer steps while holding all other parameters constant — the EE% vs. N/P curve typically shows a steep rise followed by a plateau, and operating at the plateau onset provides efficient encapsulation without excess lipid. Third, if EE% remains below target, increase ethanol fraction from 25% to 33% in 2% increments — higher ethanol content slows lipid precipitation kinetics, allowing more complete nucleic acid incorporation. For persistent low EE%, BOC Sciences offers LNP encapsulation efficiency optimization with systematic parameter screening across these variables.
Symptom: The fluorescence-based RNA quantification assay reports >85% EE%, but the total nucleic acid recovered after LNP purification (by TFF, dialysis, or centrifugal filtration) represents less than 50% of the input amount.
Differential Diagnosis: This pattern indicates that a significant fraction of the nucleic acid is lost during purification, most commonly through (a) adsorption to purification membranes or tubing, (b) co-aggregation with lipids that precipitate during buffer exchange, or (c) degradation during the time between formulation and EE% measurement — the EE% assay only measures intact, fluorescently accessible nucleic acid and can miss degraded fragments.
Systematic Approach: Quantify nucleic acid at each process step — post-mixing, post-dialysis/TFF, and post-sterile filtration — to pinpoint where the loss occurs. If loss occurs at the TFF/dialysis step, pre-condition membranes with a dilute nucleic acid solution (carrier RNA at 1 μg/mL) to saturate non-specific binding sites. If loss correlates with visible precipitate, reduce the total lipid concentration in the formulation or increase the PEG-lipid content to improve colloidal stability during buffer exchange. Verify nucleic acid integrity by gel electrophoresis or fragment analysis at each step; degradation during purification points to nuclease contamination requiring more stringent RNase-free technique.
Symptom: DLS measurement shows PDI >0.2, Z-average diameter >150 nm (for an mRNA-LNP targeting 60–90 nm), or visible turbidity/opalescence.
Differential Diagnosis: Broad size distributions arise from heterogeneous mixing conditions, while aggregation typically indicates colloidal instability driven by insufficient steric stabilization (PEG-lipid content too low), excess surface charge (N/P ratio too high), or incompatibility between the nucleic acid and the specific lipid composition.
Systematic Approach: First, increase TFR during microfluidic mixing — faster mixing reduces the time window during which partially formed particles can aggregate before PEG-lipid incorporation stabilizes their surface. Second, titrate PEG-lipid content from 1.0 to 3.0 mol% in 0.5 mol% increments; PDI typically shows a minimum at 1.5–2.5 mol%, below which steric stabilization is insufficient and above which excess PEG micelles contribute to the DLS signal. Third, if aggregation persists, screen alternative helper lipids — replacing DSPC with DOPE or adding 5–10 mol% of a negatively charged lipid (DOPG, DOPS) can reduce inter-particle electrostatic attraction. For particularly challenging formulations, LNP process optimization services can systematically evaluate mixing parameters and lipid ratios to identify conditions producing monodisperse particle populations.
Symptom: Gel electrophoresis of nucleic acid extracted from LNPs shows smearing, smaller-than-expected bands, or complete absence of the full-length band compared with the input material.
Differential Diagnosis: Damage can be chemical (RNase or DNase contamination, metal-catalyzed hydrolysis), mechanical (shear forces during mixing or filtration), or thermal (local heating during sonication or homogenization).
Systematic Approach: Run parallel controls — incubate naked nucleic acid in the formulation buffer without lipids for the duration of the encapsulation workflow; if degradation occurs, the problem is chemical (buffer, water, or consumable contamination). If the naked control remains intact but encapsulated nucleic acid is degraded, the problem is mechanical (shear during mixing) or chemical (lipid peroxidation products damaging the payload). Reduce TFR, switch to a gentler mixing geometry, or incorporate EDTA (1 mM) in the aqueous buffer to chelate metal ions that catalyze oxidative damage. For oxygen-sensitive nucleic acids, degas buffers with argon or nitrogen and include a sacrificial antioxidant. BOC Sciences offers troubleshooting services for LNP encapsulation that include systematic payload integrity assessment across the formulation workflow.
Symptom: EE% measured immediately after formulation is >85%, but drops to<70% after 24 hours at 4 °C or after a single freeze-thaw cycle.
Differential Diagnosis: Payload leakage indicates that the nucleic acid is not stably entrapped within the LNP core but is instead loosely associated with the particle surface or residing in a superficial compartment from which it can diffuse when the external buffer conditions change. This is particularly common with short oligonucleotides and with formulations using ionizable lipids with low hydrophobic anchor volume.
Systematic Approach: Increase cholesterol content to 35–45 mol% — cholesterol condenses the lipid membrane, reducing passive permeability to entrapped cargo. For short oligonucleotides, consider increasing the ionizable lipid mole fraction or switching to a multi-amine ionizable lipid that provides more electrostatic contact points per oligonucleotide molecule. Verify that the buffer exchange step is not creating an osmotic shock: match the osmolality of the dialysis/TFF exchange buffer to the formulation buffer, and perform buffer exchange gradually (stepwise rather than abrupt). Payload retention testing for LNP encapsulation from BOC Sciences provides time-course EE% monitoring under relevant storage and handling conditions to quantify leakage kinetics and guide formulation stabilization.
Symptom: EE% exceeds 80% and particle characterization (size, PDI, zeta potential) meets specifications, but the LNP produces weak or undetectable functional activity — low protein expression for mRNA, poor gene silencing for siRNA, or negligible editing for CRISPR cargos.
Differential Diagnosis: High EE% does not guarantee that the encapsulated nucleic acid is in a functionally competent state. The root cause is most commonly poor endosomal escape: the LNP is internalized by target cells but the nucleic acid is degraded in the endolysosomal compartment rather than released to the cytoplasm. Less commonly, the encapsulation process may have damaged the nucleic acid in ways not detected by the EE% assay — for example, chemical modifications (pseudouridine, N1-methylpseudouridine in mRNA) may be altered, or the 5' cap structure may be lost, rendering mRNA untranslatable despite intact length.
Systematic Approach: First, verify that the ionizable lipid pKa falls within the 6.2–6.5 window — lipids with pKa below 6.0 protonate too late in the endosomal maturation process for efficient membrane disruption, while those with pKa above 6.8 may be cytotoxic. BOC Sciences provides LNP endosomal escape evaluation using galectin recruitment assays and lysosomal co-localization analysis to quantify the fraction of LNPs that successfully disrupt the endosomal membrane. Second, if endosomal escape appears adequate, extract the nucleic acid from purified LNPs and assess its functional competence in vitro (cell-free translation for mRNA, cleavage assay for siRNA) compared with the input material. Third, consider replacing the helper lipid: DOPE in place of DSPC promotes the hexagonal phase transition that facilitates endosomal membrane fusion, potentially improving escape by 2–5 fold. LNP ionizable lipid optimization services can screen lipid candidates with varying pKa values and hydrophobic domains to identify compositions that maximize both encapsulation and functional delivery.
Table 3. Systematic Troubleshooting Guide for Common LNP Encapsulation Issues.
| Challenge | Primary Root Cause | First-Line Intervention | If Unresolved |
| Low or inconsistent EE% | Insufficient electrostatic complexation | Verify buffer pH 4.0; screen N/P 2–10 | Increase ethanol fraction 25% → 33% |
| High EE% but low total recovery | Purification loss or degradation | Quantify at each step; pre-condition membranes | Reduce lipid concentration; check nuclease contamination |
| Broad PDI / aggregation | Insufficient steric stabilization | Increase TFR; titrate PEG-lipid 1.5–2.5 mol% | Screen alternative helper lipids (DOPE, DOPG) |
| Nucleic acid damage | Shear, heat, or chemical degradation | Run naked nucleic acid control; reduce TFR | Add EDTA 1 mM; degas buffers; gentler geometry |
| Payload leakage on storage | Superficial or loose association | Increase cholesterol to 35–45 mol% | Switch to multi-amine ionizable lipid; gradual buffer exchange |
| Weak function despite high EE% | Poor endosomal escape | Verify ionizable lipid pKa 6.2–6.5 | Replace DSPC with DOPE; screen alternative ionizable lipids |
BOC Sciences provides comprehensive encapsulation development services — from method selection and parameter optimization through troubleshooting and scale-up — for mRNA, siRNA, saRNA, circRNA, pDNA, ASO, miRNA, and co-encapsulation systems.
BOC Sciences provides end-to-end support for nucleic acid-LNP encapsulation, from initial feasibility assessment through process optimization and characterization. Our approach is payload-centric: each nucleic acid type — whether a chemically modified siRNA, a long saRNA construct, or a multi-cargo co-encapsulation system — receives formulation conditions screened and optimized for its specific physicochemical properties rather than adapted from a generic protocol.
Our nucleic acid encapsulation in LNPs service begins with systematic assessment of the payload — length, charge density, secondary structure, chemical modifications, and stability profile — to define the starting formulation space. For each project, we screen ionizable lipid candidates, N/P ratios, buffer conditions, and mixing parameters using a design-of-experiments (DoE) approach that identifies not just a single working condition but the formulation landscape, revealing which parameters are most critical for robustness. Method development for LNP encapsulation is conducted with analytical methods that distinguish genuine encapsulation from surface association, ensuring reported EE% values reflect stably entrapped payload.
For teams transitioning from feasibility to preclinical development, BOC Sciences offers process development spanning staggered herringbone micromixer, hydrodynamic flow focusing, and Dean flow platforms. Process parameters — FRR, TFR, lipid concentration, nucleic acid concentration — are systematically mapped to particle quality attributes to define a design space supporting reproducible production. LNP process scale-up services address the transition from milligram to gram-scale production while maintaining particle size, PDI, EE%, and functional performance within specification.
Encapsulation quality extends beyond a single EE% number. BOC Sciences provides integrated nanoparticle analysis and characterization services covering particle size and PDI by DLS, zeta potential by electrophoretic light scattering, EE% by RiboGreen or fluorometric assay, and nucleic acid integrity by gel electrophoresis or fragment analysis. Nanoparticle morphology characterization by cryo-EM provides direct visualization of particle structure, confirming whether the nucleic acid is uniformly encapsulated or partitioned into distinct compartments. Efficiency testing for LNP encapsulation includes time-course stability assessment under relevant storage and handling conditions.
For formulations encountering persistent encapsulation challenges, BOC Sciences offers LNP lipid library screening services providing access to diverse ionizable lipid, helper lipid, and PEG-lipid libraries for formulations requiring novel lipid compositions. Co-encapsulation of multiple payloads in LNPs is supported with ratio optimization and dual-cargo quantification methods. For targeted applications, BOC Sciences also provides targeted LNP development incorporating tissue-specific or cell-type-specific ligands onto encapsulation-optimized LNP cores.
Table 4. BOC Sciences Encapsulation Services for Nucleic Acid-LNP Development.
| Service | Scope of Service | Key Deliverables | Inquiry |
| Nucleic Acid Encapsulation in LNPs | Payload-specific formulation screening, ionizable lipid selection, N/P ratio optimization, buffer and mixing parameter development for mRNA, siRNA, saRNA, circRNA, pDNA, ASO, miRNA | Optimized formulation with EE% >85%, PDI<0.15, target particle size; formulation development report | Inquiry |
| LNP Encapsulation Efficiency Optimization | Systematic N/P ratio, buffer pH, ethanol fraction, and flow rate screening; DoE-based parameter optimization; EE% improvement from current baseline | Optimized parameters achieving target EE%; robustness data across parameter ranges | Inquiry |
| Microfluidic LNP Production Services | SHM, HFF, Dean flow, and T-junction platform access; process parameter mapping; batch production from mg to g scale | Produced LNP batches with QC data; process parameter report; scale-up feasibility assessment | Inquiry |
| LNP Process Scale-Up Services | Transition from microfluidic chip to larger-scale platforms; parameter transfer and adjustment; batch consistency validation | Scale-up protocol; multiple scaled batches with comparative QC data | Inquiry |
| Co-Encapsulation of Multiple Payloads | Dual- and multi-cargo ratio optimization; homogeneous loading verification; independent cargo quantification | Co-encapsulated LNP batches with verified dual loading; cargo ratio analysis | Inquiry |
| LNP Lipid Library Screening Services | Access to diverse ionizable lipid, helper lipid, and PEG-lipid libraries; high-throughput formulation screening; structure-activity analysis | Ranked lipid candidates with EE%, size, PDI, and functional activity data; lead lipid recommendation | Inquiry |
| Troubleshooting Services for LNP Encapsulation | Root cause investigation for low EE%, aggregation, payload degradation, leakage, or poor functional performance; systematic diagnostic workflow | Diagnostic report with identified root cause; reformulation or process adjustment recommendations | Inquiry |
| LNP Endosomal Escape Evaluation | Galectin recruitment assay, lysosomal co-localization confocal imaging, functional payload expression quantification | Endosomal escape efficiency data; correlation with functional expression; formulation adjustment recommendations | Inquiry |
Successful nucleic acid encapsulation in LNPs is not a matter of following a single protocol but of understanding how method selection, formulation parameters, and payload properties interact to determine encapsulation efficiency, particle quality, and functional performance. Microfluidic self-assembly methods — particularly staggered herringbone micromixers — have become the dominant production platform because they offer the combination of high encapsulation efficiency, narrow particle size distribution, and scalability that modern nucleic acid therapeutics demand. Yet method choice must be matched to the payload: short oligonucleotides require strategies focused on retention, long mRNAs and saRNAs demand protection from shear and RNase degradation, circular RNAs need formulation conditions adapted to their constrained topology, and pDNAs present the dual challenges of large size and shear sensitivity. When encapsulation problems arise — and they nearly always do during development — systematic troubleshooting based on quantitative diagnostic indicators resolves issues far more efficiently than empirical parameter cycling. For research teams seeking to accelerate their nucleic acid-LNP programs, BOC Sciences offers integrated encapsulation development services spanning method selection, formulation optimization, process scale-up, analytical characterization, and dedicated troubleshooting — providing the expertise and infrastructure to transform encapsulation challenges into robust, reproducible LNP formulations ready for the next stage of development.
